2-(methoxycarbonylamino)-1H-benzo[d]imidazol-5-yl 2,6-dichlorobenzenesulfonate

ID: ALA4538461

PubChem CID: 87123415

Max Phase: Preclinical

Molecular Formula: C15H11Cl2N3O5S

Molecular Weight: 416.24

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  COC(=O)Nc1nc2cc(OS(=O)(=O)c3c(Cl)cccc3Cl)ccc2[nH]1

Standard InChI:  InChI=1S/C15H11Cl2N3O5S/c1-24-15(21)20-14-18-11-6-5-8(7-12(11)19-14)25-26(22,23)13-9(16)3-2-4-10(13)17/h2-7H,1H3,(H2,18,19,20,21)

Standard InChI Key:  RHTMVMVHTOFWNI-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
    6.4137   -6.4385    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.0092   -5.7327    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    5.6003   -6.4359    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.4276   -5.7327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4264   -6.5522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1345   -6.9612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1327   -5.3238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8413   -5.7291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8416   -6.5477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6202   -6.8005    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.1013   -6.1380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6198   -5.4759    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.9185   -6.1377    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.3268   -5.4298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1440   -5.4295    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.9179   -4.7223    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.5523   -4.7217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7198   -5.3243    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.3044   -5.3246    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3078   -4.5068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6008   -4.0985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8922   -4.5073    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8951   -5.3287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6026   -5.7333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6059   -6.5505    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    6.0164   -4.0998    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  9  2  0
  8  7  2  0
  7  4  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12  8  1  0
 11 13  1  0
 13 14  1  0
 14 15  1  0
 14 16  2  0
 15 17  1  0
  4 18  1  0
 18  2  1  0
  2 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 19  1  0
 24 25  1  0
 20 26  1  0
M  END

Associated Targets(Human)

MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDK9 Tchem Cyclin-dependent kinase 9 (2495 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TUBB4B Tclin Tubulin (5180 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 416.24Molecular Weight (Monoisotopic): 414.9796AlogP: 3.82#Rotatable Bonds: 4
Polar Surface Area: 110.38Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 9.57CX Basic pKa: 3.99CX LogP: 4.23CX LogD: 4.22
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.63Np Likeness Score: -1.18

References

1. Ugolini A, Kenigsberg M, Rak A, Vallée F, Houtmann J, Lowinski M, Capdevila C, Khider J, Albert E, Martinet N, Nemecek C, Grapinet S, Bacqué E, Roesner M, Delaisi C, Calvet L, Bonche F, Semiond D, Egile C, Goulaouic H, Schio L..  (2016)  Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).,  59  (15): [PMID:27355974] [10.1021/acs.jmedchem.6b00280]

Source